Title : Immunogenicity of the BA.1 and BA.4/5 Bivalent Boosts: A Brief Report of Preliminary Results from the COVAIL Randomized Clinical Trial

Authors

Angela R Branche[1]*, Nadine Rouphael[2]*, Cecilia Losada[2], Lindsey R Baden[3], Evan J Anderson[4], Anne F Luetkemeyer[5], David J Diemert[6], Patricia L Winokur[7], Rachel M Presti[8], Angelica C Kottkamp[9], Ann R Falsey[1], Sharon E Frey[10], Richard Rupp[11], Martín Bäcker[12], Richard M Novak[13], Emmanuel B Walter[14], Lisa A Jackson[15], Susan J Little[16], Lilly C Immergluck[17], Siham M Mahgoub[18], Jennifer A. Whitaker[19], Tara M. Babu[20], Paul A. Goepfert[21], Dahlene N. Fusco[22], Robert L Atmar[19], Christine M Posavad[23], Antonia Netzl[24], Derek J Smith[24], Kalyani Telu[25], Jinjian Mu[25], Mat Matkowski [25], Mamodikoe Makhene[26], Sonja Crandon[26], David C Montefiori[27], Paul C Roberts[26], John H Beigel[26]

1- University of Rochester VTEU, Rochester, NY
2- Emory University Hope Clinic, Decatur, GA
3- Brigham and Women's Hospital, Harvard Medical School, Boston, MA
4- Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA
5- Zuckerberg San Francisco General, University of California San Francisco, San Francisco, CA
6- George Washington University, Washington D.C.
7- University of Iowa College of Medicine, Iowa City, IA
8- Washington University School of Medicine, St. Louis, MO
9- NYU VTEU Manhattan Research Clinic at NYU Grossman School of Medicine, New York, NY
10- Saint Louis University, St. Louis, MO
11- University of Texas Medical Branch, League City, TX
12- NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, NY
13- University of Illinois at Chicago-Project WISH, Chicago, IL
14- Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC
15- Kaiser Permanente Washington Health Research Institute, Seattle, WA
16- Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA
17- Morehouse School of Medicine, Atlanta, GA
18- Howard University College of Medicine, Howard University Hospital, Washington D.C.
19- Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX

20- Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA

21- University of Alabama at Birmingham, Birmingham, AL

22- Tulane University School of Medicine, New Orleans, LA

23- IDCRC Laboratory Operations Unit – Fred Hutchinson Cancer Center and University of Washington, Seattle, WA

24- University of Cambridge, Cambridge, UK

25- The Emmes Company, LLC, Rockville, MD

26- Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

27- Duke University, Durham, NC

*Co-primary authors

Corresponding Author

Angela Branche, MD, FIDSA

Associate Professor of Medicine

University of Rochester

601 Elmwood Avenue

Rochester, NY 14642

Angela_branche@urmc.rochester.edu

Abstract:

The emergence of Omicron subvariants and waning immunity to initial vaccine regimens led to the authorization of updated SARS-CoV-2 bivalent vaccines containing wildtype with either Omicron BA.1 or BA.4/5. Here, we compare early serologic responses from a randomized clinical trial of a second boost with either the Pfizer/BioNTech BNT162b2 (30 mcg dose) Wildtype/Omicron BA.1 or Wildtype/Omicron BA.4/5 vaccines against homologous and heterologous strains including contemporary Omicron subvariants BQ.1.1 and XBB.1.

Brief Report:

The emergence of Omicron subvariants and waning immunity led to the authorization of updated SARS-CoV-2 bivalent vaccines containing wildtype with either Omicron BA.1 or BA.4/5 in various countries.[1,2] Currently, the predominant circulating SARS-CoV-2 strains are different Omicron subvariants with key mutations in the spike protein receptor binding domain (e.g., R346T) that further enhance the ability of the virus to escape neutralization.

Here, we compared antibody titers from 202 participants randomized 1:1 to a second boost with either the Pfizer/BioNTech BNT162b2 (30 mcg dose) Wildtype/Omicron BA.1 or Wildtype/Omicron BA.4/5 vaccines. At enrollment, 59% had a self-reported history of prior SARS-CoV-2 infection. We assessed pseudovirus neutralization titers at baseline, 15 and 29 days after vaccination against D614G, Omicron BA.1, Omicron BA.4/5 and, for a randomly selected subset of 25 samples per arm, against additional Omicron subvariants (BQ.1.1, XBB.1).

All participants were seropositive after vaccination, though the titers against all Omicron subvariants were lower than against D614G; the lowest titers were observed against XBB.1. In the Wildtype/Omicron BA.1 arm, the ID_{50} GMTs at Day 15 against D614G, BA.1 and BA.4/5 were 27,341, 6,581 and 3,585, respectively, compared to titers in the Wildtype/Omicron BA.4/5 arm of 34,094, 6,580 and 5,958, respectively. *(Figure 1A/1C, Tables 1 and 2).* Similar findings were observed at Day 29. Notably, titers against BQ.1.1 and XBB.1 were similar between the two arms. Titers against BQ.1.1 and XBB.1 were 8-22 times and 13-35 times lower than against BA.1 and D614G, respectively, with the Wildtype/Omicron BA.1 vaccine. Titers were 4-12 times and 8-22 times lower than against BA.4/5 and D614G, respectively with the Wildtype/Omicron BA.4/5 vaccine (*Figure 1B/1D, Tables 3 and 4*).

Our early immunogenicity results demonstrate better neutralization against BA.4/5 with the Wildtype/Omicron BA.4/5 vaccine. However, there was increasing neutralization escape with contemporary, late 2022, Omicron subvariants (BQ.1.1 and XBB.1) that was similar between the two bivalent vaccines even though BA.1 and BA.4/5 spike sequences are known to have different mutations in the receptor binding domain.[3] Though modest serologic advantages to Omicron BA.1 and BA.4/5 have been previously reported with bivalent compared to wildtype vaccines,[4] our findings highlight ongoing concern that the breadth of antibody response from current updated vaccines are still not optimized for the pace of virus evolution; though more precise immune correlates of protection for emerging variants are still needed. Additionally, while early vaccine effectiveness (VE) data with bivalent vaccines has emerged,[5] continuous surveillance is crucial to assess for potential VE waning.

References

1.   (2022). EMACfHMPCRpotrrfvitppavssoS-C-.
        https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf.
2.   (2022). USDoHaHSFaDAEUAfVtPC-GfI. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines.
3.   Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission. *Rev Med Virol.* 2022;32(5):e2381.
4.   Winokur P, Gayed J, Fitz-Patrick D, et al. Bivalent Omicron BA.1-Adapted BNT162b2 Booster in Adults Older than 55 Years. *N Engl J Med.* 2023;388(3):214-227.
5.   Andersson NW, Thiesson EM, Baum U, et al. Comparative effectiveness of the bivalent BA.4-5 and BA.1 mRNA-booster vaccines in the Nordic countries. *medRxiv.* 2023:2023.2001.2019.23284764.

TABLE 1. Pseudovirus Neutralization Assay Summary Results against variants of concern at baseline, 15 and 29 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.1 for all participants with and without a history a prior infection

Time Point	Statistic	D614G	BA.1	BA.4/5
Day 1	n	100	100	100
	GMT (95% CI)	7514 (6005, 9404)	1110 (844, 1460)	771 (567, 1048)
	Median (Min, Max)	6824 (193,70071)	1281 (20,17718)	955 (20,10852)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	6.77 (5.94, 7.71)	9.75 (8.19, 11.61)
	Seropositive (95% CI)	1.00 (0.96, 1.00)	0.96 (0.90, 0.99)	0.92 (0.85, 0.96)
Day 15	n	99	99	99
	GMT (95% CI)	27341 (23619, 31651)	6581 (5256, 8240)	3585 (2895, 4440)
	Median (Min, Max)	27135 (2907,127966)	6890 (322,80104)	3700 (320,40673)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	4.15 (3.63, 4.75)	7.63 (6.69, 8.70)
	GMFR (95% CI)	3.6 (3.0, 4.3)	5.8 (4.8, 7.2)	4.5 (3.6, 5.5)
	Seropositive (95% CI)	1.00 (0.96, 1.00)	1.00 (0.96, 1.00)	1.00 (0.96, 1.00)
Day 29	n	97	97	97
	GMT (95% CI)	30782 (26142, 36245)	5166 (4156, 6421)	3076 (2479, 3817)
	Median (Min, Max)	30348 (2905,221581)	5549 (194,45490)	3155 (207,36167)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	5.96 (5.22, 6.79)	10.01 (8.81, 11.37)
	GMFR (95% CI)	4.1 (3.5, 4.8)	4.6 (3.8, 5.5)	3.8 (3.1, 4.7)
	Seropositive (95% CI)	1.00 (0.96, 1.00)	1.00 (0.96, 1.00)	1.00 (0.96, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

TABLE 2. Pseudovirus Neutralization Assay Summary Results for variants of concern at baseline, 15 and 29 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.4/5 for participants with and without a history of prior infection

Time Point	Statistic	D614G	BA.1	BA.4/5
Day 1	n	100	100	100
	GMT (95% CI)	7787 (6057, 10011)	1003 (727, 1383)	735 (534, 1012)
	Median (Min, Max)	8017 (20,106523)	1395 (20,16839)	989 (20,18069)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	7.76 (6.40, 9.42)	10.59 (8.75, 12.83)
	Seropositive (95% CI)	0.99 (0.95, 1.00)	0.92 (0.85, 0.96)	0.90 (0.82, 0.95)
Day 15	n	99	99	99
	GMT (95% CI)	34094 (29523, 39371)	6580 (5159, 8393)	5958 (4648, 7636)
	Median (Min, Max)	33897 (2156,311256)	6794 (20,167899)	7119 (20,229463)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	5.18 (4.34, 6.19)	5.72 (4.78, 6.85)
	GMFR (95% CI)	4.4 (3.5, 5.4)	6.5 (5.1, 8.2)	8.0 (6.2, 10.3)
	Seropositive (95% CI)	1.00 (0.96, 1.00)	0.99 (0.95, 1.00)	0.99 (0.95, 1.00)
Day 29	n	96	96	96
	GMT (95% CI)	36666 (31189, 43105)	5070 (3928, 6542)	4915 (3829, 6310)
	Median (Min, Max)	37138 (2949,378373)	5388 (20,211797)	5840 (20,69902)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	7.23 (5.93, 8.82)	7.46 (6.15, 9.05)
	GMFR (95% CI)	4.7 (3.8, 5.9)	5.1 (4.0, 6.5)	6.6 (5.2, 8.4)
	Seropositive (95% CI)	1.00 (0.96, 1.00)	0.99 (0.94, 1.00)	0.99 (0.94, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

TABLE 3. Pseudovirus Neutralization Assay Summary Results against Omicron Subvariants at baseline and 15 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.1 for a subset of participants with and without a history a prior infection

Time Point	Statistic	D614G	BA.1	BA.4/5	BQ.1.1	XBB.1
Day 1	n	25	25	25	25	25
	GMT (95% CI)	2275 (1392, 3718)	1089 (678, 1749)	654 (344, 1245)	154 (90, 265)	39 (23, 68)
	Median (Min, Max)	2272 (207,20015)	962 (97,6668)	673 (32,8241)	146 (16,1167)	40 (5,297)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	2.09 (1.58, 2.76)	3.48 (2.35, 5.16)	14.77 (10.74, 20.32)	57.69 (42.82, 77.73)
	Seropositive (95% CI)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	0.80 (0.59, 0.93)
Day 15	n	24	24	24	24	24
	GMT (95% CI)	10529 (6843, 16201)	6551 (4442, 9662)	3587 (2072, 6210)	794 (551, 1143)	294 (194, 445)
	Median (Min, Max)	11823 (746,76974)	5823 (722,33414)	3946 (248,24941)	759 (101,4297)	282 (20,2199)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	1.61 (1.23, 2.09)	2.94 (2.02, 4.27)	13.27 (10.41, 16.91)	35.82 (27.35, 46.91)
	GMFR (95% CI)	4.4 (3.1, 6.4)	5.7 (3.8, 8.5)	4.9 (3.4, 7.1)	4.7 (3.3, 6.8)	6.8 (4.5, 10.5)
	Seropositive (95% CI)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

TABLE 4. Pseudovirus Neutralization Assay Summary Results for Omicron Subvariants at baseline and 15 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.4/5 for a subset of participants with and without a history of prior infection

Time Point	Statistic	D614G	BA.1	BA.4/5	BQ.1.1	XBB.1
Day 1	n	25	25	25	25	25
	GMT (95% CI)	1842 (1222, 2776)	1213 (683, 2154)	610 (316, 1177)	148 (88, 249)	52 (31, 87)
	Median (Min, Max)	1414 (523,11934)	1624 (76,11967)	729 (27,9429)	140 (5,2103)	71 (5,543)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	1.52 (1.11, 2.08)	3.02 (2.01, 4.52)	12.43 (8.82, 17.52)	35.54 (25.16, 50.20)
	Seropositive (95% CI)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	0.96 (0.80, 1.00)	0.88 (0.69, 0.97)
Day 15	n	25	25	25	25	25
	GMT (95% CI)	8967 (5911, 13604)	6921 (4942, 9691)	6140 (4321, 8725)	1077 (810, 1433)	398 (281, 563)
	Median (Min, Max)	7594 (1124,63821)	7754 (888,37374)	4987 (1713,43534)	1105 (331,3731)	402 (113,1883)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	1.30 (0.91, 1.84)	1.46 (0.94, 2.27)	8.32 (6.01, 11.54)	22.56 (15.50, 32.83)
	GMFR (95% CI)	4.9 (3.0, 7.8)	5.7 (3.6, 9.1)	10.1 (6.2, 16.4)	7.3 (4.6, 11.5)	7.7 (5.0, 11.9)
	Seropositive (95% CI)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)	1.00 (0.86, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

FIGURE 1. Pseudovirus Neutralization ID$_{50}$ Titers by Timepoint (baseline, Day 15 and Day 29) and Variant, (D614G, Omicron BA.1 [B.1.1.529], BA.4/BA.5, BQ.1.1 and XBB.1) before and after vaccination with 30 mcg of Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.1 (A and C) or 30 mcg Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.4/5 (B and D). Boxes with horizontal bars denote interquartile range (IQR) and median ID$_{50}$, respectively. Whisker denotes 95% confidence interval. LLOD, lower limit of detection of the assay. GMT, geometric mean titer. GMFR, geometric mean fold rise from baseline.

Pfizer Wildtype + Omicron BA.4/5 Vaccine

GMFR	1.0	4.4	4.7		1.0	6.5	5.1		1.0	8.0	6.6
GMT	7787	34094	36666		1003	6580	5070		735	5958	4915
GMR $_{D614G}$	1.00	1.00	1.00		7.76	5.18	7.23		10.59	5.72	7.46
N	100	99	96		100	99	96		100	99	96

Day Post Vaccination by variant

Pfizer Wildtype + Omicron BA.1 Vaccine

GMFR	1.0	4.4	1.0	5.7	1.0	4.9	1.0	4.7	1.0	6.8
GMT	2275	10529	1089	6551	654	3587	154	794	39	294
GMR $_{D614G}$	1.00	1.00	2.09	1.61	3.48	2.94	14.77	13.27	57.69	35.82
N	25	24	25	24	25	24	25	24	25	24

ID$_{50}$

LLOD=10

1 15   1 15   1 15   1 15   1 15

D614G   BA.1   BA.4/5   BQ.1.1   XBB.1

Day Post Vaccination by variant

Pfizer Wildtype + Omicron BA.4/5 Vaccine

GMFR	1.0	4.9	1.0	5.7	1.0	10.1	1.0	7.3	1.0	7.7
GMT	1842	8967	1213	6921	610	6140	148	1077	52	398
GMR D614G	1.00	1.00	1.52	1.30	3.02	1.46	12.43	8.32	35.54	22.56
N	25	25	25	25	25	25	25	25	25	25

ID_{50}

10^5

10^4

10^3

10^2

LLOD=10

1	15	1	15	1	15	1	15	1	15
D614G		BA.1		BA.4/5		BQ.1.1		XBB.1	

Day Post Vaccination by variant

SUPPLEMENTAL MATERIALS

Study Design and Eligibility Criteria

This phase 2 open-label, randomized, clinical trial was performed at 20 sites in the US (Supplemental Table 7) enrolling all participants in October 2022. Eligible participants were healthy adults between the ages of 18 to 49 years of age (with or without a history of prior SARS-CoV-2 infection) who had received a primary series and a single homologous or heterologous boost with an approved or emergency use authorized COVID-19 vaccine (Supplemental Table 8). The most recent vaccine dose, and/or prior infection must have occurred at least 16 weeks prior to randomization. Full eligibility criteria are described at clinicaltrials.gov (NCT 05289037).

Two hundred and two eligible participants were stratified by history of confirmed SARS-CoV-2 infection, and randomly assigned for each stage in an equal ratio.

After informed consent, participants underwent screening, including confirmation of COVID-19 vaccination, medical history, a targeted physical examination, and a urine pregnancy test (if indicated). Samples were collected at Day 1, Days 15 and 29, and 3, 6, 9 and 12 months after vaccination. Immunologic data are currently available up to the Day 29 after vaccination.

The trial was reviewed and approved by a central institutional review board and overseen by an independent Data and Safety Monitoring Board. Participants provided written informed consent before undergoing trial-related activities. The trial was sponsored and funded by the National Institutes of Health (NIH). The NIAID SARS-CoV-2 Assessment of Viral Evolution (SAVE) program team was consulted to inform study arm design and variant vaccine selection.

Trial vaccine

Trial vaccines were provided by Pfizer BioNTech (total amount of 30 mcg per vaccine; 15 mcg of each component). The vaccine candidates are manufactured similarly to their corresponding authorized or approved vaccines in the US or Europe.

Study outcomes

The primary objective was to evaluate humoral immune responses of candidate SARS-CoV-2 variant vaccines.

Immunogenicity assays

SARS-CoV-2 neutralization titers, expressed as the serum inhibitory dilution required for 50% neutralization (ID_{50}), were assessed using pseudotyped lentiviruses[1] presenting SARS-CoV-2 spike mutations for the D614G, (Wuhan-1 containing a single D614G spike mutation), B.1.1.529 (Omicron BA.1), Omicron BA.4/BA.5, Omicron BQ.1.1 and Omicron XBB.1 as described previously[6] on a random subset of samples (25 per vaccine arm, distributed roughly equally

between infected and uninfected). All samples (101 per vaccine arm) were tested in a commercial lab for the following strains: D614G, Omicron BA.1, Omicron BA.4/5.

Pre-specified immunogenicity endpoints
Statistical analysis

The primary objective of this study is to evaluate the magnitude and breadth of SARS-CoV-2 specific antibody titers in serum samples by estimating 95% confidence intervals (CI) for the geometric mean titer (GMT) at each timepoint when samples are collected. No formal hypothesis tests were planned. The geometric mean fold rise (GMFR) is calculated as the geometric mean of titers at a timepoint divided by titers at Day 1. The geometric mean ratio to D614G (GMR_{D614G}) is the geometric mean of the ratio of titers for a variant of concern to titers against D614G. Seropositive rate is calculated as the proportion of participants with titers above the lower limit of detection (LLOD). 95% CI for GMT, GMFR, and GMR_{D614G} are calculated using the Student's t-distribution and 95% CI for seropositive rate is calculated using the Clopper-Pearson binomial method. For the purpose of analysis, participants were defined as previously infected by self-report of a confirmed positive antigen or PCR testing. Participants with COVID-19 occurring between vaccination and a pre-specified immunogenicity timepoint were not selected for this immunogenicity analysis.

Supplemental References

1. Shen X, Chalkias S, Feng J, et al. Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination. *N Engl J Med.* 2022;387(13):1234-1236.

COVAIL Manuscript Study Members

Emory University Hope Clinic, Decatur, GA

Nadine G. Rouphael, MD; Cecilia Losada, MD; Daniel S. Graciaa, MD; Hady Samaha, MD; Cassie Grimsley Ackerley, MD; Kristen E. Unterberger, PA; Amy Anderson, BSN; Mary Atha, ACNP; Kareem Bechnak, BSN; Sarah Bechnak, BSN; Mary Bower, BSN; Laura Clegg, RN; Matthew Collins, MD, PhD; Francine Dyer, RN; Srilatha Edupuganti, MD; Rebecca Fineman, BS; Tigisty Girmay, MSN; Rebecca Gonzalez, PharmD; Natalie Gray, BS; Evan Gutter, MPH; Lisa Harewood; Chris Huerta, MSc; Brandi Johnson, BS; Lauren Johnson, MPH; Colleen Kelley, MD; Alexandra Koumanelis, BA; Deborah Laryea, BSN; Hollie Macenczak, BSN; Nour Makkaoui, MD; Michele McCullough, MPH; Tuong-Vy Ngo, PharmD; Eileen Osinski, BS; Julia Paine, BS; Bernadine Panganiban, BS; Rose Pope, RN; Paulina Rebolledo, MD; Susan Rogers, RPh; Erin Scherer, PhD; Veronica Smith, NP-C; Andre Stringer, BS; Jessica Traenkner, PA; Dongli Wang, BS; Alahna Watson, BA; Stacey Wheeler, RN; Jean Winter; Jianguo Xu, PhD

Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Lindsey R. Baden, MD; Amy C. Sherman, MD; Stephen R. Walsh, MD; Alexandra Tong, BS; Rebecca Rooks, BS; Jane A. Kleinjan, NP; Jon A. Gothing, NP; Andres A. Avila Paz, BA; Muneerah M. Aleissa, PharmD, MPH; Bethany Evans, BA, August Heithoff, BS; Natalie E. Izaguirre, MS; Hannah Jin, MPH; Urwah Kanwal, BS; Austin Kim, BS; Julia E. Klopfer, BS; Christina Montesano, BS; John Almeida, BA; Emily S. Koleske, BS; Hannah Levine, BS; Nicholas P. Morreale, BS; Omolola Ometoruwa, BS; Jun Bai Park Chang, BS; Anna F. Piermattei, BA; Djenane M. Pierre, BS; Megan Powell, BA; Kevin Zinchuk, PharmD; Stephanie Pickford, PharmD; Charles M. Kelly III, PharmD; Xiaofang Li, PhD; John Kupelian, BS ; Kimberly Dufresne, BS; Xiaoguang Fan, MD, PhD; Xi Zhang, PhD; Esther Arbona-Haddad, MD; Jose Humberto Licona, MD

Center for Childhood Infections and Vaccines (CCIV) of Children's Healthcare of Atlanta and Emory University Department of Pediatrics, Atlanta, GA

Evan J. Anderson, MD; Christina A. Rostad, MD; Satoshi Kamidani, MD; Etza Peters, RN; Larry Anderson, MD; Julia Bartol; Leisa Bower RN; Natsuko Campbell RN; Lisa Harewood, Hui-Mien Hsiao, Laila Hussaini MPH, Inara Jooma, Gidget Kettle RN; Marcia Lewis RN; Wensheng Li; Cindy Lubbers RN; Lisa Macoy RN; Molly Morrison, Heather Nurse RN; Anna Siaw-Anim; Kathleen Stephens RN; Madeline Taylor; Ashley Tippett MPH; Lauren Nolan PA

Zuckerberg San Francisco General, University of California San Francisco, San Francisco, CA

Anne F. Luetkemeyer, MD; Chloe Harris, BA; Azquena Munoz Lopez, BS; Daniel Berrner; Dennis Dentoni-Lasofsky, MSN; John Dwyer, RN; Suzanne Hendler, BSN; Elvira Gomez, MPH; WeyLing Phuah, PharmD; Jaime Velasco, BA; Veronica Viar, MS

George Washington University, Washington D.C.

David J. Diemert, MD; Elissa Malkin, DO; Jeffrey M. Bethony, PhD; Aimee Desrosiers, PA-C; Marc Siegel, MD; Nikita Schroll-McLaughlin, MS; Jonathan Manning, BA; Jane Ryu, MS; Hanna-Grace Rabanes, MPH; Khadija Khan, MPH; Laura Vasquez, MPH; Caroline Thoreson, PA-C; Larissa Scholte, PhD; Rafaela Thur, DVM; Peyton St. John, BS; Dorinne Mettle-Amuah, PharmD

University of Iowa College of Medicine, Iowa City, IA

Patricia L. Winokur, MD; Jeffery Meier, MD; Jack Stapleton, MD; Laura Stulken, PA; Theresa Hegmann, PA; Deb Pfab, RN; Elizabeth Morgan, RN; Susan Herman, RN; Angel Peguero, CMA; Michelle Rodenburg; Alfred J. Carr; Delilah Johnson

Washington University School of Medicine, St. Louis, MO

Rachel M. Presti, MD, PhD; Jane A. O'Halloran, MD, PhD; Michael Klebert, RN, PhD Ryley M. Thompson; Alem Haile; Kim Gray, NP; Chapelle Ayres; Delaney Carani, RN; Michael Royal; John Tran; Laura Blair; Anita Afghanzada; Natalie Schodl

NYU VTEU Manhattan Research Clinic at NYU Grossman School of Medicine, New York, NY

Angelica C. Kottkamp, MD; Tamia Davis, NP; Celia Engelson, NP; Vijaya Soma, MD; Abdulwahab Abdulai; Ashanay Allen; Natella Aronova, NP; Philip Aziz, PharmD; Emily Beato; Samuel Bliss, PharmD; Jacqueline Callahan, RN; Ellie Carmody, MD; Amanda Dontino, BS; Aimee Edwin, RN; Shelby Goins; Sarah Haiken; Ramin Herati, MD; Abdonnie Holder; Janice Hong; Trishala Karmacharya; Manpreet Kaur, PharmD; Hye-Youn Kim; Alexander McMeeking, MD; Mark Mulligan, MD; Wai Ng; Edward Nirenberg; Irma Noriega, NP; Samuel Nweke; Lalitha Parameswaran, MD; Levonne Phillip, MPH; Stephanie Rettig, MPH; Marie Samanovic-Golden, PhD; Madalyn Saporito; Pamela Suman; Meron Tasissa; Michael Tuen; Julia Wagner, MPH; James Wilson; Doris Wong, PharmD; Grace Yip, BS; Samantha Yip, RN; Heekoung Youn, RN; Lisa Zhao

University of Rochester VTEU, Rochester, NY

Angela R. Branche, MD, Ann R. Falsey, MD, Edward Walsh, MD, Patrick Kingsley, BS, Arthur Zemanek, BSN, MS Katherine Elena, BSN, Spencer Obrecht, BSN, Ian Shannon, BSN, Amy Kaychalo, BS, MS, Erin Nowicki, Sharon Moorehead, Kari Steinmetz, BA, Doreen Francis, RN, Tanya Smith, BS, William Hamilton, BS, Jeanne Holden-Wiltse, MPH, MBA, Christopher Lane, MS, Michael Peasley, BS, Samuel Diehl, BS, Kyle Richards, PharmD, Stephen Bean, PharmD, Nicole Dornbush, PharmD, Carol Cole, PharmD

Saint Louis University, St. Louis, MO

Sharon E. Frey, MD; Getahun Abate, MD, PhD; Zacharoula Oikonomopoulou, MD; Daniel F. Hoft, PhD, MD; Irene Graham, MD; Azra Blazevic, DVM, MPH; Tamara Blevins, MS; Kathleen Chirco, BSN; Sabrina M. DiPiazza, BSN, MA; Stanley Doublin; Heather Hoertel Douds, MSNS, BSN; Carol G. Duane, PhD, RN; Eric Eggemeyer, BA; Linda M. Eggemeyer-Sharpe, BSN;

Lauren Nicole Foreman, BSN; Sarah Louise George, MD; Geoffrey J. Gorse, MD; Michelle Harris, PharmD; Helay Hassas, PharmD; Rong Hou, MD; Ryan Clark Kerr, BSN; Kate Elizabeth Liefer, BSN; Melissa J. Loyet, RN; Lainey Mejia-Jauregui, BS; Keith Meyer, BS; Tracy Renee Montauk, BSN; Karla J. Mosby, RN; Amanda Nethington, BS; Huan Ning, MD; Nicole Purcell; Joan M. Siegner, BSN, MA; Janice M. Tennant, BSN, MPH; Mei Xia, PhD; Kiana Wilder, BA; Yinyi Yu, BS; Cassandra Nicole Zehenny, BSN

University of Texas Medical Branch, League City, TX

Richard Rupp, MD; Laura Porterfield, MD; Amber Stanford, PA-C; Robert Cox, RN; Kristin Pollock, RN; Diane Barrett, MS; Gerrianne Casey, RN; Amy McMahan, LVN; Cori Burkett, PA-C; Essie Cox

NYU VTEU Long Island Research Clinic at NYU Long Island School of Medicine, Mineola, NY

Martín Bäcker, MD, Kimberly Byrnes, RN, Asif Noor, MD, Andrew B. Fleming, MD, Sigridh A. Muñoz-Gómez, MD, Diana Badillo, MD, Steven E. Carsons, MD, Sajumon K. Joseph, FNP, Sarah J. Pastolero, RN, Sophie Danziger, Monica Benitez, Maung Aung, Louis Ragolia, PhD, Alicia Vasile, RPh, April Correll, RPh, Christopher Hall, Thomas Palaia, Miloni H Thakker, MD, Lavern Harvey, Lisa Zhao

University of Illinois at Chicago-Project WISH, Chicago, IL

Richard M. Novak, MD; Benjamin G. Ladner, MD; Andrea Wendrow, RPh; Jesica Herrick, MD; Alfredo J. Mena Lora, MD; Scott A. Borgetti, MD; Diana L Bahena, APRN; Regina Harden, BA; Renyce Powell; David C. M. Chan, PharmD; Rebeca F. Gasari, PharmD; Michael Pacini, PharmD; Margarita M. Villarreal, CPhT; Rodrigo Reyes, ADN; Samuel M. Rene, MPH; Shannon M Whitted, BSN; Habiba Sultana, MBBS; Nanu Kunwar, BS; Tasmin Sultana, MBBS; Md R. Amin, PhD; Mahmood Ghassemi, PhD, Liam Morrissy, BS; Nia O'Neal, BS; Chasity Serrano, BS; Charlie Peterson, BA

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC

Emmanuel B. Walter MD, MPH; Michael J. Smith MD, MSCE; M. Anthony Moody, MD; Kenneth E. Schmader, MD; Susan Doyle; Lynn S Harrington BSN; Lori Hendrickson BSN; Amy O'Berry MSN; Sherry Huber BSN; Janet Wootton RN, RSCN; Kelly Clark BA; Lani Banez; Stephanie Smith BA; Byron Hauser BS; Ally Odom BA; Emily Randolph BA; Krystina Yoder BA; Kathlene Chmielewski; Luis Ballon BA; Aubree Latorre; Breana Montgomery; Antony Tritz MS; Thad Gurley, MS; Margaret Pendzich

Kaiser Permanente Washington Health Research Institute, Seattle, WA

Lisa A. Jackson, MD, MPH; Maya Dunstan, MS, RN; Rebecca Lau, PharmD; Barbara Carste, MPH; Wesley A. Andersen, RPh, MHA, MA; Lee Barr, RN; Jesse Berg, BS; Cassandra Bryant, BS; Joe Choe, BS; Jana ffitch, LPN; Lynn Gross, PA-C; Erika Kiniry, MPH; Bonnie Y Lam, PharmD; De Vona Lang; Jasmine S. Lau, BS; Stella Lee, BA; Paula J Lins, PA-C, MPH; Amy

Mohelnitzky, PA-C; Marilyn Nguyen, BS; Matthew Nguyen, MPH; Hallie Phillips, MEd; Stephanie Pimienta, BS; Melissa Resendiz Rivas, BA; Melissa Boothe Scheer, PA-C; Janice Suyehira, MD; Stacie Wellwood, LPN; Maryann K Woodford, PA-C

Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California San Diego, La Jolla, CA

Susan J. Little, MD; Thomas C.S. Martin, MD; Nicole Carter, MPH; Steven Hendrickx, RN; Ajay Bharti, MD; Alyssa Phillips; Aurora Verduzco Gonzalez, NP; Cheryl Dullano; Chris Houston; Dawn Rosenblum, RN; DeeDee Pacheco; DeLys Brooks; Fang Wan; Helene Le, CPhiT; JC Alcantar; Jill Blumenthal, MD; Joseph Lencioni, MABMH; Kory Hess; Letty Muttera, PharmD; Marlene Arredondo; Megan Smyth; Megan Taylor; Melinda Stafford, PharmD; Michelle Orsburn, MD; Michelle Truong; Niamh Higgins, PharmD, MSc, AAHIVP; Nimish Patel, PharmD, PhD, AAHIVP; Rebecca Gonzalez; Vivian Maldonado

Morehouse School of Medicine, Atlanta, GA

Lilly C. Immergluck, MD; Erica Johnson, PhD; Austin Chan, MD; Fatima Ali, MPH; Sonja Jackson; Noor Mohamed, PharmD; LaKesha Tables, MD; Norberto Fas, MD; Kay Woodson, PharmD; Saadia Khizer, MD; Jacquelyn Ali, MSA; Abdullah Warsama; Eric Gaines; Sierra Jordan Thompson; Cristina Wilson; Trisha Parker, MPH; Xiting Lin; LaTeshia Thomas Seaton, APRN, Derrick Wilson

Howard University College of Medicine, Howard University Hospital, Washington D.C.

Siham M. Mahgoub, MD; Celia Maxwell, MD; Sarah Shami, PharmD; Edward Bauer, BS; Yuanxiu Chen, MD, PhD; Megan Ware-Pressley, MHA; Debra Ordor, RN; Linda Fletcher, RN; Emmanuel Baidoo, BS; David Jaspan, RPh, MBA; Adetokunbo Adedokun, PharmD, MPH, BCPS; Michelle Strobeck, BS; Michael A. Riga; Ashley Karen Bautista, BS

Departments of Molecular Virology and Microbiology and Medicine, Baylor College of Medicine, Houston, TX

Jennifer A. Whitaker, MD; Hana M. El Sahly, MD; Wendy A. Keitel, MD; C. Mary Healy, MD; Robert L. Atmar, MD; Pedro A. Piedra, MD; Jesus Banay; Kathy Bosworth; Janet Brown, RPh; Kayla Burrell; Jeremy Castro; Tykel Eddy; Marcena Eubanks; Cathy Faw, RPh; Rachel Froebe; Alix Halter, RN; Janey John, MSN, APRN, FNP-C; Chanei Henry, AAS; Vanessa Martinez; Carol Mundell, RN; Brandie Phillips, RN; Alicia Prevost-Barthe, RN; Connie Rangel, RN; Yolanda Rayford, MS; Yvette Rugeley; Maria Shlyapobersky; Tina Sierra; Elizabeth Silguero; Lisreina Toro; Dawn Turner, RN; Chianti Wade-Bowers, RN; Jessica Woods, RN

Departments of Medicine, Epidemiology, and Laboratory Medicine & Pathology, University of Washington, Vaccines and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA

Tara M. Babu, MD, MSCI; Anna Wald, MD, MPH; Taylor Krause, BA; Kirsten Hauge, MPH; Jina Taub, ARNP, Dana Varon, ARNP, Britt Murphy, ARNP, Morissa Pertik, PA-C, T. Nui Pholsena,

ARNP, Alyssa Braun, BS, Mark Drummond, BS, Jessica Heimonen, MPH, Amy Link, BS, Lindsey McClellan, BS, Jessica Moreno, BS, Chloe Wilkens, BS, Matt Seymour, MPH, Lawrence Hemingway, BS, Jean Mernaugh, BS, Chris McClurkan, BS, Kerry Laing, PhD, Meredith Potochnic, PharmD, Joong Kim, PharmD, Bao-Chao Vo, PhT, Dil Singh, BS

University of Alabama at Birmingham, Birmingham, AL

Paul A. Goepfert, MD; Jenna Weber, RN; Savannah Spaulding, RN; Heather Logan, CRNP; Faye Heard; Foreamben Patel; Michelle Chambers

Tulane University School of Medicine, New Orleans, LA

Dahlene N. Fusco, MD; Arnaud C. Drouin, MD; Florice K. Numbi, MD; Hamada F. Rady, PhD; Crystal A. Ward, MSN; Quinn M. Powers, MS; William E. Casey, BS; Brian P. Logarbo, MD; Shae P. Williams, BS; Emily Callegari, MSN

IDCRC Principal Investigators

David S. Stephens, MD; Kathleen M. Neuzil, MD

IDCRC Leadership Operations Center

Monica M. Farley, MD; Jeanne Marrazzo, MD; Sidnee Paschal Young

IDCRC Clinical Operations Unit

Jeffery Lennox, MD; Robert L. Atmar, MD; Linda McNeil FHI360

IDCRC Laboratory Operations Unit – Fred Hutchinson Cancer Center and University of Washington, Seattle, WA

Christine M. Posavad, PhD; Megan A. Meagher, BS; Michael Stirewalt, MBA; John Hural, PhD; Weston Lawler, BA; Lexi Tanser, MA, Julie McElrath, MD, PhD; Mike Gale, PhD

IDCRC Statistical and Data Science Unit

Elizabeth Brown, PhD

The Emmes Company, LLC, Rockville, MD

Mat Makowski, PhD; Heather Hill, MS; Jim Albert, MS, Holly Baughman; Lisa McQuarrie, MS; Kalyani Telu, MS; Jinjian Mu, PhD

Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD

Teri C. Lewis, BS; Lisa A. Giebeig, MS; Theresa M. Engel, MFS.; Caleb J. Griffith, MPH; Wendi L. McDonald, BSN; Alissa E. Burkey, MS; Lisa B. Hoopengardner, MS; Jessica E. Linton, MS; Nikki L. Gettinger, MPH; Aroussiak Bowen; Beth R. Baseler, MS; Vanessa S. Eccard-Koons, MS; Charles W. R. Hofsommer, JD; Thomas C. Sova, JD; Gary A. Krauss

Duke Laboratory, NC

David C Montefiori, MD, Amanda Eaton, MBA, Francesca Suman, MS.

Smith's Laboratory, Cambridge, UK

Derek J Smith, PhD; Antonia Netzl; Samuel H Wilks, PhD; Sina Tureli, PhD; Ana Mosterín Höpping, PhD; Samuel Turner; Sarah James, MD; Poppy Roth

Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

Marina Lee, PhD; Mamodikoe Makhene, MD; Mohamed Elsafy, MD; Rhonda Pikaart-Tautges, BS; Janice Arega, MS: Binh Hoang, RPh; Dan Curtin; Hyung Koo, BSN; Elisa Sindall, BSN; Aya Nakamura, RN, MS; Audria Crowder, BS; Guinevere Chun, RN, BSN, MSHS; Frank Kenny, PhD MPH; Seemi Patel, RHP, PharmD; Sonia Gales, MS; Ahsen Khan, JD; Walla Dempsey, PhD; Robert Jurao- RN, BSN; Sonja Crandon, BSN; Seema U. Nayak, MD; Marciela M DeGrace, PhD; Diane J Post, PhD; Paul C Roberts, PhD, John H Beigel, MD SAVE Program

TABLE S1. Pseudovirus Neutralization Assay Summary Results against variants of concern at baseline, 15 and 29 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.1 for uninfected participants

Time Point	Statistic	D614G	BA.1	BA.4/5
Day 1	n	41	41	41
	GMT (95% CI)	5085 (3344, 7732)	651 (390, 1085)	374 (213, 658)
	Median (Min, Max)	5265 (193,39415)	857 (20,13125)	433 (20,5325)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	7.82 (6.27, 9.74)	13.58 (9.83, 18.76)
	Seropositive (95% CI)	1.00 (0.91, 1.00)	0.90 (0.77, 0.97)	0.80 (0.65, 0.91)
Day 15	n	40	40	40
	GMT (95% CI)	23561 (18002, 30838)	4699 (3153, 7001)	2398 (1636, 3515)
	Median (Min, Max)	24076 (2907,127966)	4448 (322,69891)	2333 (320,40673)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	5.01 (4.02, 6.26)	9.83 (7.81, 12.35)
	GMFR (95% CI)	4.6 (3.4, 6.2)	7.1 (5.0, 10.1)	6.0 (4.1, 8.7)
	Seropositive (95% CI)	1.00 (0.91, 1.00)	1.00 (0.91, 1.00)	1.00 (0.91, 1.00)
Day 29	n	40	40	40
	GMT (95% CI)	25507 (18682, 34824)	3870 (2587, 5788)	2241 (1520, 3304)
	Median (Min, Max)	26325 (2905,180227)	4369 (194,45490)	2060 (207,28017)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	6.59 (5.44, 7.99)	11.38 (9.30, 13.92)
	GMFR (95% CI)	5.0 (3.7, 6.6)	5.8 (4.3, 7.8)	5.5 (4.0, 7.8)
	Seropositive (95% CI)	1.00 (0.91, 1.00)	1.00 (0.91, 1.00)	1.00 (0.91, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

TABLE S2. Pseudovirus Neutralization Assay Summary Results against variants of concern at baseline, 15 and 29 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.4/5 for uninfected participants

Time Point	Statistic	D614G	BA.1	BA.4/5
Day 1	n	41	41	41
	GMT (95% CI)	4492 (2779, 7260)	465 (247, 873)	334 (179, 623)
	Median (Min, Max)	4950 (20,106523)	464 (20,12329)	441 (20,18069)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	9.66 (6.73, 13.87)	13.46 (9.20, 19.69)
	Seropositive (95% CI)	0.98 (0.87, 1.00)	0.80 (0.65, 0.91)	0.76 (0.60, 0.88)
Day 15	n	40	40	40
	GMT (95% CI)	30673 (23854, 39443)	4166 (2576, 6737)	3751 (2356, 5972)
	Median (Min, Max)	31554 (2156,284099)	4266 (20,157116)	3119 (20,79102)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	7.36 (5.08, 10.68)	8.18 (5.64, 11.86)
	GMFR (95% CI)	6.8 (4.4, 10.6)	8.8 (5.5, 14.2)	11.0 (6.6, 18.3)
	Seropositive (95% CI)	1.00 (0.91, 1.00)	0.98 (0.87, 1.00)	0.98 (0.87, 1.00)
Day 29	n	40	40	40
	GMT (95% CI)	31302 (23939, 40929)	3351 (2064, 5441)	3262 (2073, 5132)
	Median (Min, Max)	35767 (2949,333162)	3753 (20,211797)	3160 (20,69902)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	9.34 (6.21, 14.06)	9.60 (6.44, 14.30)
	GMFR (95% CI)	7.0 (4.4, 11.1)	7.1 (4.4, 11.5)	9.6 (6.0, 15.2)
	Seropositive (95% CI)	1.00 (0.91, 1.00)	0.98 (0.87, 1.00)	0.98 (0.87, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

TABLE S3. Pseudovirus Neutralization Assay Summary Results against Omicron Subvariants at baseline and 15 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.1 for a subset of uninfected participants

Time Point	Statistic	D614G	BA.1	BA.4/5	BQ.1.1	XBB.1
Day 1	n	12	12	12	12	12
	GMT (95% CI)	1422 (670, 3020)	571 (300, 1087)	272 (99, 745)	95 (39, 231)	21 (10, 45)
	Median (Min, Max)	1171 (207,7795)	708 (97,2053)	324 (32,3259)	129 (16,1088)	33 (5,103)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	2.49 (1.67, 3.71)	5.23 (2.71, 10.07)	14.99 (8.74, 25.71)	67.20 (43.14, 104.68)
	Seropositive (95% CI)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	0.67 (0.35, 0.90)
Day 15	n	11	11	11	11	11
	GMT (95% CI)	8258 (3868, 17630)	4712 (2376, 9342)	2055 (796, 5309)	602 (319, 1137)	200 (101, 394)
	Median (Min, Max)	8213 (746,76974)	4010 (722,32928)	1398 (248,22686)	588 (101,4297)	221 (20,798)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	1.75 (1.27, 2.42)	4.02 (2.23, 7.24)	13.72 (10.02, 18.78)	41.32 (27.88, 61.25)
	GMFR (95% CI)	5.5 (3.0, 10.2)	7.7 (3.7, 15.9)	6.4 (3.1, 13.3)	5.5 (2.7, 11.3)	8.3 (3.7, 18.5)
	Seropositive (95% CI)	1.00 (0.72, 1.00)	1.00 (0.72, 1.00)	1.00 (0.72, 1.00)	1.00 (0.72, 1.00)	1.00 (0.72, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

TABLE S4. Pseudovirus Neutralization Assay Summary Results against Omicron subvariants at baseline and 15 days after vaccination with Pfizer/BioNTech BNT162b2 Wildtype/Omicron BA.4/5 for a subset of uninfected participants

Time Point	Statistic	D614G	BA.1	BA.4/5	BQ.1.1	XBB.1
Day 1	n	12	12	12	12	12
	GMT (95% CI)	1622 (779, 3377)	947 (318, 2816)	496 (155, 1587)	136 (50, 374)	44 (18, 106)
	Median (Min, Max)	1212 (523,11934)	1549 (76,11967)	703 (27,8660)	146 (5,2103)	64 (5,453)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	1.71 (0.98, 2.98)	3.27 (1.64, 6.52)	11.91 (6.39, 22.20)	37.23 (20.47, 67.70)
	Seropositive (95% CI)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	0.92 (0.62, 1.00)	0.83 (0.52, 0.98)
Day 15	n	12	12	12	12	12
	GMT (95% CI)	11849 (6252, 22458)	6751 (4007, 11374)	6753 (4020, 11344)	1220 (817, 1820)	431 (238, 782)
	Median (Min, Max)	9444 (3239,63821)	7139 (888,22532)	6927 (2146,32980)	1218 (386,3731)	398 (113,1883)
	GMR $_{D614G}$ (95% CI)	1.00 (NE)	1.76 (0.89, 3.46)	1.75 (0.77, 3.99)	9.71 (5.40, 17.47)	27.49 (13.76, 54.92)
	GMFR (95% CI)	7.3 (3.1, 17.0)	7.1 (2.9, 17.4)	13.6 (5.8, 31.9)	9.0 (3.9, 20.8)	9.9 (4.6, 21.3)
	Seropositive (95% CI)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)	1.00 (0.74, 1.00)

n=Number of subjects with results available at time point

Confidence intervals of the geometric means were calculated with the Student's t distribution on log-transformed data

TABLE S9. List of COVAIL US Sites

Site name

George Washington University

University of Rochester Medical Center

Hope Clinic of the Emory Vaccine Center

Brigham and Women's Hospital, Harvard Medical School

Saint Louis University

Baylor College of Medicine

University of California San Diego

Emory Center for Childhood Infections and Vaccines of Children's Healthcare of Atlanta

Duke Human Vaccine Institute, Duke University School of Medicine

University of Illinois at Chicago, Project WISH

University of Texas Medical Branch

Kaiser Permanente Washington Health Research Institute

University of Washington

New York University Manhattan Research Clinic, NYU Grossman School of Medicine

Zuckerberg San Francisco General Hospital, University of California at San Francisco

Morehouse School of Medicine

Washington University School of Medicine

NYU Long Island Research Clinic, NYU Long Island School of Medicine

University of Iowa College of Medicine

Howard University Hospital, Howard University Hospital

University of Alabama at Birmingham

Tulane University School of Medicine

TABLE S10. Eligible Regimens for Primary Vaccination Series and Boost

Primary series vaccine manufacturer	Number of doses in primary series	Primary series dose	Interval between 1st and 2nd dose	Number of booster doses	Booster dose	Allowed interval between primary series and booster dose*
Pfizer BioNTech	2	30 µg	At least 17 days	1	30 µg	≥ 5 months
Moderna	2	100 µg	At least 24 days	1	50 µg	≥ 5 months
Janssen	1	5×10^{10} viral particles	Not applicable	1	5×10^{10} viral particles	≥ 2 months

*homologous and heterologous boosters are acceptable

^ no participant had prior NVX-CoV2373 vaccine as booster with this vaccine was approved after the start of the study on October 4, 2022.